Table. Subject Accountability at 96 Weeks

	DTG			EFV
Premature withdrawal, n (%)	**10 mg (n=53)**	**25 mg (n=51)**	**50 mg (n=51)**	**600 mg (n=50)**
AE	1 (2)	1 (2)	2 (4)	6 (12)
Lack of efficacy	1 (2)	1 (2)	0	0
Protocol deviation	1 (2)	1 (2)	1 (2)	0
Lost to follow-up	0	2 (4)	1 (2)	1 (2)
Decision by subject or proxy	3 (6)	1 (2)	1 (2)	2 (4)

AE, adverse event; DTG, dolutegravir; EFV, efavirenz.

Table. Summary of Treatment-Emergent Clinical Chemistry Toxicities for Selected Laboratory Parameters at 96 Weeks

	DTG				EFV
Maximum treatment-emergent toxicity, n (%)	**10 mg (n=53)**	**25 mg (n=51)**	**50 mg (n=51)**	**Subtotal (n=155)**	**600 mg (n=50)**
Alanine aminotransferase					
Grade 1	6 (11)	7 (14)	2 (4)	15 (10)	12 (24)
Grade 2	1 (2)	3 (6)	1 (2)	5 (3)	6 (12)
Grade 3	0	1 (2)	0	1 (<1)	0
Grade 4	0	0	0	0	1 (2)
Lipase					
Grade 1	2 (4)	3 (6)	3 (6)	8 (5)	3 (6)
Grade 2	8 (15)	8 (16)	4 (8)	20 (13)	4 (8)
Grade 3	1 (2)	1 (2)	4 (8)	6 (4)	1 (2)
Grade 4	0	1 (2)	0	1 (<1)	1 (2)
Total bilirubin					
Grade 1	3 (6)	3 (6)	2 (4)	8 (5)	0
Grade 2	0	1 (2)	1 (2)	2 (1)	0
Creatine kinase					
Grade 1	7 (13)	2 (4)	6 (12)	15 (10)	4 (8)
Grade 2	4 (8)	2 (4)	1 (2)	7 (5)	1 (2)
Grade 3	2 (4)	1 (2)	0	3 (2)	0
Grade 4	4 (8)	1 (2)	0	5 (3)	0

DTG, dolutegravir; EFV, efavirenz.

Table. Summary of Serum Creatinine and Urine Protein

	DTG				EFV
Parameter	**10 mg (n=53)**	**25 mg (n=51)**	**50 mg (n=51)**	**Subtotal (n=155)**	**600 mg (n=50)**
Baseline serum creatinine, mean, µmol/L	82.0	88.1	82.2	84.1	79.5
Change in serum creatinine from baseline, mean (SD), µmol/L					
Week 1	8.5 (8.04)	9.0 (8.85)	12.2 (6.63)	9.8 (8.03)	1.1 (7.79)
Week 16	8.1 (8.83)	7.0 (9.77)	12.4 (9.39)	9.1 (9.55)[a]	0.8 (6.99)
Week 24	4.4 (9.15)	5.1 (11.91)	10.6 (7.75)	6.6 (10.08)[a]	-2.0 (10.08)
Week 48	2.7 (9.16)	1.1 (11.38)	6.3 (7.76)	3.4 (9.69)[a]	-6.0 (10.19)
Week 96	3.6 (7.59)	2.1 (11.43)	10.1 (11.07)	5.2 (10.64)[a]	-2.4 (8.79)
Urine albumin/creatinine ratio at week 96, mg/mmol creatinine				NR	
n	38	33	38		34
Mean	1.06	0.91	0.97		1.56
SD	1.699	0.950	1.113		2.908
Range	0.2-9.4	0.3-5.2	0.3-6.2		0.2-16.3

DTG, dolutegravir; EFV, efavirenz; NR, not reported; SD, standard deviation.

[a] $P < 0.001$ vs EFV.